Measurement of sleep-onset REM episodes during sleep with and without sleep deprivation- «SOREM Episodes: state or trait?»

Not Applicable

Conditions: G47.4
G47
Narcolepsy and cataplexy
Sleep disorders

Registration Number: DRKS00029645

Lead Sponsor: Klinik Barmelweid

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 90

Inclusion Criteria

• Subjective symptoms of daytime sleepiness (definition see below)
• Epworth Sleepiness Scale (ESS) >10/24 points
• At least 1 SOREM episode in previous routine MSLT and/or in routine PSG at time of diagnosis.
• The patients must be at least 18 years old and no more than 80 years old
• Ability and consent to electrophysiological testing
• Ability to give informed consent

Exclusion Criteria

• Pregnant or breastfeeding women
• Drug therapy with sodium oxybate
• Inability to follow the instructions on the study procedures due to language problems, mental disorders, dementia, etc.
• Presence of comorbid diseases that make sleep deprivation impossible (e.g. epilepsy)
• Evidence of accidentally found epilepsy-typical potentials in the baseline night investigation that make sleep deprivation impossible
• The following diseases/conditions considered to cause hypersomnolence and SOREMs on clinical grounds:
o Other neurological disorders (e.g. stroke, multiple sclerosis, Parkinson's disease, severe traumatic brain injury, epilepsy)
o Unstable psychiatric disorders (including acute psychoses, acute suicidality, severe depression, drug abuse)
o Active infectious disease (e.g. encephalitis)

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The aim of the study is to gain new insights into the clinical picture of narcolepsy and other diseases from the group of central hypersomnolence (narcolepsy, idiopathic hypersomnia, non-organic hypersomnia, chronic sleep deficiency syndrome, sleep apnea). The study can improve the diagnosis and classification of these diseases. New objective measurements are to be obtained that will enable simpler, faster and more precise diagnosis. New treatment options for drugs may also be derived from this.

Secondary Outcome Measures